Satralizumab Biosimilar - Anti-IL6R mAb - Research Grade
Source
CAS 1535963-91-7
Species
Humanized
Expression system
Mammalian cells
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Satralizumab,SA-237,IL6R,anti-IL6R
Reference
PX-TA1407
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG2-kappa
Clonality
Monoclonal Antibody
Description of Satralizumab Biosimilar - Anti-IL6R mAb - Research Grade
General information on Anti-IL6R[Homo sapiens] (Satralizumab) Monoclonal Antibody
Satralizumab is a humanized monoclonal antibody that targets human interleukin-6 (IL-6) receptors, similar to tocilizumab. Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD). Increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased permeability of the blood-brain barrier are thought to be mediated by IL-6. Satralizumab is thought to block IL-6 receptors and, thereby, these inflammatory responses.
Satralizumab Biosimilar - Anti-IL6R mAb binds to CD126 Recombinant Protein in indirect ELISA Assay
Immobilized CD126 Recombinant Protein (cat. No.PX-P4104) at 0.5µg/mL (100µL/well) can bind to Satralizumab Biosimilar - Anti-IL6R mAb (cat. No.PX-TA1407) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Satralizumab Biosimilar – Anti-IL6R mAb – Research Grade” Cancel reply
Related products
Antigen
Human CD126, IL6R, Interleukin-6 receptor subunit alpha recombinant protein
Reviews
There are no reviews yet.